Bristol Myers Squibb (BMS), one of the world’s largest biopharmaceutical companies, has unveiled Mosaic, a first-of-its-kind, AI-powered content hub, marking a new era of tech-accelerated patient care. 

Launched in partnership with global professional services firm Accenture, the new hub signals a major leap forward in AI-driven pharmaceutical commercialization. 

Located in Mumbai, Mosaic is an end-to-end, generative AI-enabled platform that will strengthen BMS’s digital capabilities by identifying physicians’ educational needs in real time and rapidly producing patient-centric content at scale. The initiative underscores BMS’s ambition to lead the next phase of technology-enabled healthcare engagement. 

The Mosaic content hub was officially inaugurated by Adam Lenkowsky, Chief Commercialization Officer of Bristol Myers Squibb, alongside Ndidi Oteh, Global CEO of Accenture Song. 

“The future of healthcare is about meeting clinicians and patients where they are and doing so in meaningful ways. This partnership reflects our BMS approach to end-to-end digital transformation,” said Adam Lenkowsky, Chief Commercialization Officer, Bristol Myers Squibb.  

“The Mosaic content hub will ultimately improve patient experience by making it easier for our marketing teams to create and share timely, tailored communications with health care professionals.” 

India plays a critical role in Bristol Myers Squibb’s global strategy. The company has maintained commercial operations in the country for more than two decades, delivering medicines across oncology, hematology, and cardiology.  

Recently, BMS expanded its footprint with the opening of a state-of-the-art facility in Hyderabad, employing more than 3,000 professionals across Business Insights and Technology, Global Drug Development, Global Product Development and Supply, and Enabling Functions. 

BMS is investing $130 million to advance a broad portfolio of AI initiatives across marketing and commercialization, with Mosaic forming a key component of that investment. By leveraging India’s deep digital expertise and collaborative ecosystem, the company aims to scale next-generation, AI-driven solutions across its global operations. 

Bristol Myers Squibb’s science-led, patient-centric mission is increasingly being propelled by advances in artificial intelligence and machine learning.  

“We are strategically leveraging and integrating AI tools across BMS to unlock efficiency, enable access to data, boost productivity and enhance decision-making – all with the goal of helping our global workforce reinvent our industry.” said Anvita Karara, Vice President, Worldwide Commercialization Excellence. 

The Mosaic launch also builds on a long-standing relationship between BMS and Accenture, partners for more than 25 years. What began as a traditional services engagement has evolved into a deep collaboration focused on innovation, digital transformation, and operational excellence. 

The Mumbai-based content hub will bring together a large, multidisciplinary team of creatives and technologists to modernize how marketing content is developed and delivered at scale.  

“Accenture and Bristol Myers Squibb are leading the AI-forward reinvention of biopharma by applying innovative technologies to generate meaningful outcomes for patients. Mosaic is a powerful example of how Bristol Myers Squibb is driving industry transformation and setting a new standard for hyper-personalized experiences for healthcare professionals,” added Oteh.